Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

SHA:600664 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	16,151	16,119	15,400	13,755	12,741	10,741
Other Revenue	56.83	56.83	56.21	53.63	61.06	47.59
Revenue	16,208	16,176	15,457	13,809	12,802	10,788
Revenue Growth (YoY)	3.45%	4.65%	11.93%	7.86%	18.66%	-8.76%
Cost of Revenue	11,751	11,655	11,443	10,446	9,826	8,543
Gross Profit	4,457	4,521	4,013	3,363	2,976	2,245
Selling, General & Admin	3,275	3,390	3,143	2,565	2,306	2,824
Research & Development	142.29	136.43	106.02	115.81	97.73	92.53
Other Operating Expenses	126.75	108.29	120.17	122.65	113.17	104.39
Operating Expenses	3,585	3,671	3,395	2,805	2,528	3,049
Operating Income	871.92	849.71	618.44	557.91	447.79	-803.3
Interest Expense	-56.88	-60.07	-56.47	-85.53	-105.16	-58.27
Interest & Investment Income	42.58	49.47	51.58	69.19	16.5	50.42
Currency Exchange Gain (Loss)	-5.68	-5.68	-5.37	3	1.99	-0.83
Other Non Operating Income (Expenses)	66.17	66.61	-22.74	-19.44	-5.07	-176.52
EBT Excluding Unusual Items	918.12	900.04	585.45	525.13	356.06	-988.49
Gain (Loss) on Sale of Investments	-	-	-	-20	-	-
Gain (Loss) on Sale of Assets	2.36	0.94	0.98	161.38	210.87	14.1
Asset Writedown	-61.79	-59.84	-15.13	-32.52	-2.33	-74.72
Other Unusual Items	42.91	33.87	79.25	67.17	65.93	80.47
Pretax Income	901.6	875.01	650.54	701.15	630.53	-968.65
Income Tax Expense	182.58	184.4	176.32	188.94	220.69	76.6
Earnings From Continuing Operations	719.03	690.61	474.22	512.21	409.85	-1,045
Minority Interest in Earnings	-53.99	-61.76	-78.95	-47.06	-38.76	-32.45
Net Income	665.03	628.85	395.26	465.15	371.08	-1,078
Net Income to Common	665.03	628.85	395.26	465.15	371.08	-1,078
Net Income Growth	47.88%	59.10%	-15.02%	25.35%	-	-
Shares Outstanding (Basic)	2,550	2,515	2,470	2,448	2,474	2,506
Shares Outstanding (Diluted)	2,550	2,515	2,470	2,584	2,474	2,506
Shares Change (YoY)	2.39%	1.82%	-4.40%	4.46%	-1.29%	-10.19%
EPS (Basic)	0.26	0.25	0.16	0.19	0.15	-0.43
EPS (Diluted)	0.26	0.25	0.16	0.18	0.15	-0.43
EPS Growth	44.43%	56.25%	-11.11%	20.00%	-	-
Free Cash Flow	492.76	691.69	863.14	532.45	-239.13	-846.37
Free Cash Flow Per Share	0.19	0.28	0.35	0.21	-0.10	-0.34
Gross Margin	27.50%	27.95%	25.96%	24.35%	23.24%	20.81%
Operating Margin	5.38%	5.25%	4.00%	4.04%	3.50%	-7.45%
Profit Margin	4.10%	3.89%	2.56%	3.37%	2.90%	-9.99%
Free Cash Flow Margin	3.04%	4.28%	5.58%	3.86%	-1.87%	-7.85%
EBITDA	1,077	1,066	878.27	821.32	716.99	-433.54
EBITDA Margin	6.65%	6.59%	5.68%	5.95%	5.60%	-4.02%
D&A For EBITDA	205.41	216.29	259.83	263.41	269.2	369.75
EBIT	871.92	849.71	618.44	557.91	447.79	-803.3
EBIT Margin	5.38%	5.25%	4.00%	4.04%	3.50%	-7.45%
Effective Tax Rate	20.25%	21.07%	27.10%	26.95%	35.00%	-
Revenue as Reported	16,208	16,176	15,457	13,809	12,802	10,788
Advertising Expenses	-	1,806	1,574	1,058	340.89	201.29

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.